Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (OTCMKTS:MURGY) Downgraded by Jefferies Financial Group

Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (OTCMKTS:MURGY) was downgraded by stock analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a report issued on Monday, Briefing.com reports.

Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München Stock Performance

Shares of MURGY stock opened at $54.80 on Monday. The company has a current ratio of 1.12, a quick ratio of 1.12 and a debt-to-equity ratio of 0.20. The stock has a 50 day simple moving average of $53.26 and a 200-day simple moving average of $49.90. The company has a market cap of $74.78 billion, a price-to-earnings ratio of 13.96, a price-to-earnings-growth ratio of 0.69 and a beta of 1.02. Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München has a 12-month low of $39.08 and a 12-month high of $55.71.

Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (OTCMKTS:MURGY) last released its quarterly earnings data on Thursday, August 8th. The financial services provider reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.07. The company had revenue of $16.10 billion for the quarter. On average, equities analysts forecast that Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München will post 5.75 EPS for the current year.

Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München Company Profile

Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München engages in the insurance and reinsurance businesses worldwide. It also offers life and health reinsurance solutions, such as digital underwriting and advanced analytics solutions, health insurance management system, financial market risks, financing, portfolio risk management, digitalized investment-linked solution, MIRA digital suite, MIRA POS, MIRApply insured and physician, claims risk adjustment, CLARA plus, data analytics, underwriting and claims, medical research, capital management, and health market.